EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS
https://doi.org/10.21518/2079-701X-2017-3-58-62
Abstract
Obesity is a chronic disease associated with cardiometabolic risk factors of cardiovascular diseases and type 2 diabetes. In 2016, in Russia a new drug was registered for the treatment of patients with adiposity - liraglutide 3.0 mg, which is an analog of human glucagonoma peptide-1. The study purpose: to study the efficacy of liraglutide 3.0 mg/day and its impact on cardiometabolic risk factors in patients with obesity. We examined 30 patients aged 25-59 with obesity without diabetes. Patients received therapy with liraglutide 3.0 mg/day for 3 months. The examination included measurement of anthropometric parameters, blood sampling with the estimation of the parameters of lipid and carbohydrate metabolism.
Results: after 3 months of treatment with liraglutide 3.0 mg a significant improvement of anthropometric parameters was observed: reduction of weight, BMI and waist circumference and a significant improvement in parameters of metabolic comorbidities.
Conclusions: complex therapy with use of liraglutide 3.0 mg per day for 3 months is effective for therapy of obesity and correction of obesity-associated cardiometabolic disturbances.
About the Authors
K. A. Komshilova
Scientific Centre of Endocrinology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine,
Moscow
E. A. Troshina
Scientific Centre of Endocrinology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof., corresponding member of RAS,
Moscow
E. V. Ershova
Scientific Centre of Endocrinology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicne,
Moscow
O. V. Logvinova
Scientific Centre of Endocrinology of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ, 2001, 2(9): 56–60.
2. Astrup A1, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond), 2013 Feb, 37(2): 322.
3. Dombrowski SU, Knittle K, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ, 2014, 348: 2646.
4. Jensen MD, Ryan MD, Donato SM, et al. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Published by The Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. // Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring), 2014, 22(suppl 2): 5-39.
5. Wadden TA1, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond), 2013 Nov, 37(11): 1514.
6. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization, 1998.
Review
For citations:
Komshilova KA, Troshina EA, Ershova EV, Logvinova OV. EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS. Meditsinskiy sovet = Medical Council. 2017;(3):58-62. (In Russ.) https://doi.org/10.21518/2079-701X-2017-3-58-62
Views:
609
Email this article 